Adding baricitinib to HIV treatment to control the virus
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests a pill called baricitinib (already used for arthritis) to see if adding it to your HIV medications can help control the virus long-term. You might join if your HIV is well controlled and you are generally healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be living with HIV and taking HIV medications for at least 2 years without stopping.
- Your viral load (amount of virus in your blood) must be undetectable for at least 2 years.
- You must have a CD4 count of 500 or higher and have never had a CD4 count below 200.
- You must be between 18 and 70 years old.
- You must not be pregnant or breastfeeding.
- You must not have a history of certain health problems, like heart disease, blood clots, or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).
This study tests whether giving a small protein called IL-15 can help your immune system keep HIV under control after pausing your daily HIV medications. You will stop your meds for a short time under careful monitoring, and the hope is that your body might learn to fight HIV without daily pills.
This study tests a new combo pill for HIV (ainuovirine, lamivudine, and tenofovir) against a standard pill (efavirenz, lamivudine, and tenofovir) in people who have both HIV and tuberculosis. It aims to find a treatment that works well and has fewer side effects.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This Phase 2 study tests baricitinib to see if it can lower HIV activity in the brain (CNS) for people already on stable HIV treatment. If you have well-controlled HIV in your blood, this trial looks for additional benefit inside the nervous system.
This trial tests whether a medication that targets inflammation in the body can help relieve depression symptoms. You will have blood tests and an MRI to see how your brain and immune system respond.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.